DALLAS, April 15, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Hemispherx Biopharma Inc. (AMEX:HEB). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: www.microstockprofit.com/ads/HEB
Hemispherx Biopharma Inc. (HEB) is a biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's products include Ampligen and Alferon N Injection. Ampligen is an experimental drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS) and as a vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N is an indicator for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is an application under early stage development targeting influenza and viral diseases.
In the report, the analyst notes:
"HEB announced its financial results for the fiscal year ended December 31, 2009. The net loss for the year (including non-cash charges) was approximately $13,438,000 or $0.12 per share as compared to a net loss of $12,219,000 or $0.16 per share in 2008. This $1,219,000 increase in loss was primarily due to increased research and development expenses associated with preparing the New Brunswick, New Jersey manufacturing plant for increased production plus efforts employed in supporting the New Drug Application ("NDA") and employee compensation awards.
"HEB is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for the treatment of seriously debilitating disorders, and Max Neeman International is one of the leading and largest clinical research organizations ("CROs") in India. The companies recently jointly announced a collaborative clinical research effort for one of HEB's flagship products, Alferon N Injection® (interferon Alfa-n3)."
To read the entire report visit: www.microstockprofit.com/ads/HEB
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.